Skip to main content

Advertisement

SpringerLink
Log in

Re-visiting Hypersensitivity Reactions to Taxanes: A Comprehensive Review

  • Published:
Clinical Reviews in Allergy & Immunology Aims and scope Submit manuscript

Abstract

Taxanes (a class of chemotherapeutic agents) are an important cause of hypersensitivity reactions (HSRs) in cancer patients. During the last decade, the development of rapid drug desensitization has been key to allow patients with HSRs to taxanes to be safely re-treated although the mechanisms of these HSRs are not fully understood. Earlier studies suggested that solvents, such as Cremophor EL used to solubilize paclitaxel, were responsible for HSRs through complement activation, but recent findings have raised the possibility that some of these HSRs are IgE-mediated. Taxane skin testing, which identifies patients with an IgE-mediated sensitivity, appears as a promising diagnostic and risk stratification tool in the management of patients with HSRs to taxanes. The management of patients following a HSR involves risk stratification and re-exposure could be performed either through rapid drug desensitization or graded challenge based on the severity of the initial HSR and the skin test result. Rapid drug desensitization has been shown to be an effective and safe method to re-introduce taxanes in hundreds of patients, including those with life-threatening HSRs. Patients with non-severe delayed skin HSRs may benefit from rapid drug desensitization since they may be at increased risk for an immediate HSR upon re-exposure. This review focuses on the clinical presentation, diagnosis, and novel mechanisms of immediate HSRs to taxanes. A new management strategy for HSRs to taxanes based on skin testing and rapid drug desensitization is proposed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Limsuwan T, Castells MC (2010) Outcomes and safety of rapid desensitization for chemotherapy hypersensitivity. Expert Opin Drug Saf 9:39–53

    Article  CAS  PubMed  Google Scholar 

  2. Morgan RJ, Alvarez RD, Armstrong DK et al (2012) Ovarian cancer, version 3.2012. J Natl Compr Canc Netw 10:1339–49

    CAS  PubMed  Google Scholar 

  3. Castells MC, Tennant NM, Sloane DE et al (2008) Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol 122:574–80

    Article  CAS  PubMed  Google Scholar 

  4. Caiado J, Venemalm L, Pereira-Santos M, Costa L, Barbosa M, Castells M (2013) Carboplatin-, oxaliplatin-, and cisplatin–specific IgE: cross-reactivity and value in the diagnosis of carboplatin and oxaliplatin allergy. J Allergy Clin Immunol Pract 1:494–500

    Article  PubMed  Google Scholar 

  5. Mezzano V, Giavina-Bianchi P, Picard M, Caiado J, Castells M (2013) Drug desensitization in the management of hypersensitivity reactions to monoclonal antibodies and chemotherapy. BioDrugs 28:133–44

    Article  CAS  Google Scholar 

  6. Prieto Garcia A, Pineda de la Losa F (2010) Immunoglobulin E-mediated severe anaphylaxis to paclitaxel. J Investig Allergol Clin Immunol 20:170–1

    CAS  PubMed  Google Scholar 

  7. Picard M, Pur L, Caiado J, Galvao V, Giavina-Bianchi P, Castells M (2014) Added value of skin testing in hypersensitivity reactions to taxanes [Abstract]. J Allergy Clin Immunol 133:AB152

    Article  Google Scholar 

  8. Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT (1971) Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 93:2325–7

    Article  CAS  PubMed  Google Scholar 

  9. Schiff PB, Fant J, Horwitz SB (1979) Promotion of microtubule assembly in vitro by taxol. Nature 277:665–7

    Article  CAS  PubMed  Google Scholar 

  10. Jordan MA, Wilson L (2004) Microtubules as a target for anticancer drugs. Nat Rev Cancer 4:253–65

    Article  CAS  PubMed  Google Scholar 

  11. Horwitz SB (1994) How to make taxol from scratch. Nature 367:593–4

    Article  CAS  PubMed  Google Scholar 

  12. Exposito O, Bonfill M, Moyano E et al (2009) Biotechnological production of taxol and related taxoids: current state and prospects. Anticancer Agents Med Chem 9:109–21

    Article  CAS  PubMed  Google Scholar 

  13. Nicolaou KC, Yang Z, Liu JJ et al (1994) Total synthesis of taxol. Nature 367:630–4

    Article  CAS  PubMed  Google Scholar 

  14. Taxol Prescribing Information (2014) (Accessed January 13, 2014, at http://packageinserts.bms.com/pi/pi_taxol.pdf.)

  15. Taxotere Prescribing Information (2013) (Accessed December 24, 2013, at http://products.sanofi.us/Taxotere/taxotere.html.)

  16. Stinchcombe TE (2007) Nanoparticle albumin-bound paclitaxel: a novel Cremphor-EL-free formulation of paclitaxel. Nanomedicine (Lond) 2:415–23

    Article  CAS  Google Scholar 

  17. Cucinotto I, Fiorillo L, Gualtieri S et al (2013) Nanoparticle albumin bound paclitaxel in the treatment of human cancer: nanodelivery reaches prime-time? J Drug Deliv 2013:905091

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  18. Kratz F (2008) Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release 132:171–83

    Article  CAS  PubMed  Google Scholar 

  19. Desai N, Trieu V, Yao Z et al (2006) Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of Cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 12:1317–24

    Article  CAS  PubMed  Google Scholar 

  20. Ma P, Mumper RJ (2013) Paclitaxel nano-delivery systems: a comprehensive review. J Nanomed Nanotechnol 4:1000164

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  21. Abraxane Prescribing Information (2014) (Accessed January 3, 2014, at http://abraxane.com/downloads/Abraxane_PrescribingInformation.pdf.)

  22. Galsky MD, Dritselis A, Kirkpatrick P, Oh WK (2010) Cabazitaxel. Nat Rev Drug Discov 9:677–8

    Article  CAS  PubMed  Google Scholar 

  23. Cabazitaxel Prescribing Information (2014) (Accessed January 12, 2014, at http://products.sanofi.us/jevtana/jevtana.html.)

  24. Wiernik PH, Schwartz EL, Strauman JJ, Dutcher JP, Lipton RB, Paietta E (1987) Phase I clinical and pharmacokinetic study of taxol. Cancer Res 47:2486–93

    CAS  PubMed  Google Scholar 

  25. Kris MG, O'Connell JP, Gralla RJ et al (1986) Phase I trial of taxol given as a 3-hour infusion every 21 days. Cancer Treat Rep 70:605–7

    CAS  PubMed  Google Scholar 

  26. Weiss RB, Donehower RC, Wiernik PH et al (1990) Hypersensitivity reactions from taxol. J Clin Oncol 8:1263–8

    CAS  PubMed  Google Scholar 

  27. Gennari A, Salvadori B, Tognoni A, Conte PF (1996) Rapid intravenous premedication with dexamethasone prevents hypersensitivity reactions to paclitaxel. Ann Oncol 7:978–9

    Article  CAS  PubMed  Google Scholar 

  28. Bookman MA, Kloth DD, Kover PE, Smolinski S, Ozols RF (1997) Short-course intravenous prophylaxis for paclitaxel-related hypersensitivity reactions. Ann Oncol 8:611–4

    Article  CAS  PubMed  Google Scholar 

  29. Markman M, Kennedy A, Webster K, Peterson G, Kulp B, Belinson J (1997) Simplified regimen for the prevention of paclitaxel-associated hypersensitivity reactions. J Clin Oncol 15:3517

    CAS  PubMed  Google Scholar 

  30. Micha JP, Rettenmaier MA, Dillman R, Fraser P, Birk C, Brown JV (1998) Single-dose dexamethasone paclitaxel premedication. Gynecol Oncol 69:122–4

    Article  CAS  PubMed  Google Scholar 

  31. Olson JK, Sood AK, Sorosky JI, Anderson B, Buller RE (1998) Taxol hypersensitivity: rapid retreatment is safe and cost effective. Gynecol Oncol 68:25–8

    Article  CAS  PubMed  Google Scholar 

  32. Cormio G, Di Vagno G, Melilli GA et al (1999) Hypersensitivity reactions in ovarian cancer patients receiving paclitaxel. J Chemother 11:407–9

    Article  CAS  PubMed  Google Scholar 

  33. Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J (2000) Paclitaxel-associated hypersensitivity reactions: experience of the gynecologic oncology program of the Cleveland Clinic Cancer Center. J Clin Oncol 18:102–5

    CAS  PubMed  Google Scholar 

  34. Kwon JS, Elit L, Finn M et al (2002) A comparison of two prophylactic regimens for hypersensitivity reactions to paclitaxel. Gynecol Oncol 84:420–5

    Article  CAS  PubMed  Google Scholar 

  35. Henry A, Charpiat B, Perol M, Vial T, de Saint Hilaire PJ, Descotes J (2006) Paclitaxel hypersensitivity reactions: assessment of the utility of a test-dose program. Cancer J 12:237–45

    Article  CAS  PubMed  Google Scholar 

  36. Kosmas C, Tsavaris N (2006) A simplified premedication protocol for one-hour paclitaxel infusion in various combinations. Med Sci Monit 12:CR462–6

    CAS  PubMed  Google Scholar 

  37. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD et al (1994) European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 12:2654–66

    CAS  PubMed  Google Scholar 

  38. Sendo T, Sakai N, Itoh Y et al (2005) Incidence and risk factors for paclitaxel hypersensitivity during ovarian cancer chemotherapy. Cancer Chemother Pharmacol 56:91–6

    Article  CAS  PubMed  Google Scholar 

  39. Kloover JS, den Bakker MA, Gelderblom H, van Meerbeeck JP (2004) Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens. Br J Cancer 90:304–5

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  40. Williams C, Bryant A (2011) Short versus long duration infusions of paclitaxel for any advanced adenocarcinoma. Cochrane Database Syst Rev 11:CD003911

    Google Scholar 

  41. Smith RE, Brown AM, Mamounas EP et al (1999) Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-26. J Clin Oncol 17:3403–11

    CAS  PubMed  Google Scholar 

  42. Kelly CM, Green MC, Broglio K et al (2012) Phase III trial evaluating weekly paclitaxel versus docetaxel in combination with capecitabine in operable breast cancer. J Clin Oncol 30:930–5

    Article  CAS  PubMed  Google Scholar 

  43. Mannel RS, Brady MF, Kohn EC et al (2011) A randomized phase III trial of IV carboplatin and paclitaxel ×3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol 122:89–94

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  44. Quock J, Dea G, Tanaka M, Gandara D, Lara P, Lau D (2002) Premedication strategy for weekly paclitaxel. Cancer Invest 20:666–72

    Article  CAS  PubMed  Google Scholar 

  45. Markman M, Blessing J, Rubin SC, Connor J, Hanjani P, Waggoner S (2006) Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study. Gynecol Oncol 101:436–40

    Article  CAS  PubMed  Google Scholar 

  46. Braverman AS, Rao S, Salvatti ME, Adamson B, McManus M, Pierre S (2005) Tapering and discontinuation of glucocorticoid prophylaxis during prolonged weekly to biweekly paclitaxel administration. Chemotherapy 51:116–9

    Article  CAS  PubMed  Google Scholar 

  47. Schrijvers D, Wanders J, Dirix L et al (1993) Coping with toxicities of docetaxel (Taxotere). Ann Oncol 4:610–1

    CAS  PubMed  Google Scholar 

  48. Mertens WC, Eisenhauer EA, Jolivet J, Ernst S, Moore M, Muldal A (1994) Docetaxel in advanced renal carcinoma. A phase II trial of the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 5:185–7

    CAS  PubMed  Google Scholar 

  49. Pazdur R, Lassere Y, Soh LT et al (1994) Phase II trial of docetaxel (Taxotere) in metastatic colorectal carcinoma. Ann Oncol 5:468–70

    CAS  PubMed  Google Scholar 

  50. Francis PA, Rigas JR, Kris MG et al (1994) Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer. J Clin Oncol 12:1232–7

    CAS  PubMed  Google Scholar 

  51. Semb KA, Aamdal S, Oian P (1998) Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment. J Clin Oncol 16:3426–32

    CAS  PubMed  Google Scholar 

  52. Piccart MJ, Gore M, Ten Bokkel HW et al (1995) Docetaxel: an active new drug for treatment of advanced epithelial ovarian cancer. J Natl Cancer Inst 87:676–81

    Article  CAS  PubMed  Google Scholar 

  53. Cortes JE, Pazdur R (1995) Docetaxel. J Clin Oncol 13:2643–55

    CAS  PubMed  Google Scholar 

  54. Vasey PA, Jayson GC, Gordon A et al (2004) Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 96:1682–91

    Article  CAS  PubMed  Google Scholar 

  55. Syrigou E, Dannos I, Kotteas E et al (2011) Hypersensitivity reactions to docetaxel: retrospective evaluation and development of a desensitization protocol. Int Arch Allergy Immunol 156:320–4

    Article  CAS  PubMed  Google Scholar 

  56. Poi MJ, Berger M, Lustberg M et al (2013) Docetaxel-induced skin toxicities in breast cancer patients subsequent to paclitaxel shortage: a case series and literature review. Support Care Cancer 21:2679–86

    Article  PubMed Central  PubMed  Google Scholar 

  57. Piccart MJ, Klijn J, Paridaens R et al (1997) Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer. J Clin Oncol 15:3149–55

    CAS  PubMed  Google Scholar 

  58. Schwartz JR (2012) Dexamethasone premedication for prophylaxis of taxane toxicities: can the doses be reduced when paclitaxel or docetaxel are given weekly? J Oncol Pharm Pract 18:250–6

    Article  CAS  PubMed  Google Scholar 

  59. Sparano JA, Wang M, Martino S et al (2008) Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 358:1663–71

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  60. Gradishar WJ, Tjulandin S, Davidson N et al (2005) Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23:7794–803

    Article  CAS  PubMed  Google Scholar 

  61. Yamamoto Y, Kawano I, Iwase H (2011) Nab-paclitaxel for the treatment of breast cancer: efficacy, safety, and approval. Onco Targets Ther 4:123–36

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  62. de Leon MC, Bolla S, Greene B, Hutchinson L, Del Priore G (2013) Successful treatment with nab-paclitaxel after hypersensitivity reaction to paclitaxel and docetaxel. Gynecol Oncol Case Rep 5:70–1

    Article  PubMed Central  PubMed  Google Scholar 

  63. Kimura K, Tanaka S, Iwamoto M et al (2013) Safety of nanoparticle albumin-bound paclitaxel administered to breast cancer patients with clinical contraindications to paclitaxel or docetaxel: Four case reports. Oncol Lett 6:881–4

    PubMed Central  PubMed  Google Scholar 

  64. Fader AN, Rose PG (2009) Abraxane for the treatment of gynecologic cancer patients with severe hypersensitivity reactions to paclitaxel. Int J Gynecol Cancer 19:1281–3

    Article  PubMed  Google Scholar 

  65. Micha JP, Goldstein BH, Birk CL, Rettenmaier MA, Brown JV 3rd (2006) Abraxane in the treatment of ovarian cancer: the absence of hypersensitivity reactions. Gynecol Oncol 100:437–8

    Article  CAS  PubMed  Google Scholar 

  66. Fernandez O, Afonso J, Vazquez S, et al (2014) Metastatic castration-resistant prostate cancer: changing landscape with cabazitaxel. Anticancer Drugs 25(3):237–43

    Google Scholar 

  67. de Bono JS, Oudard S, Ozguroglu M et al (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376:1147–54

    Article  PubMed  CAS  Google Scholar 

  68. Bracarda S, Gernone A, Gasparro D, et al (2013) Real-world cabazitaxel safety: the Italian early-access program in metastatic castration-resistant prostate cancer. Future Oncol. doi:10.2217/fon.13.256

  69. Tannock IF, de Wit R, Berry WR et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502–12

    Article  CAS  PubMed  Google Scholar 

  70. Pivot X, Koralewski P, Hidalgo JL et al (2008) A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Ann Oncol 19:1547–52

    Article  CAS  PubMed  Google Scholar 

  71. Anonymous (2011) A fatal anaphylactic reaction to paclitaxel is described, which was preceded by a possible delayed reaction to the initial infusion. Allergy Asthma Proc 32:79

  72. Hiraki A, Aoe K, Murakami T, Maeda T, Eda R, Takeyama H (2004) Stevens-Johnson syndrome induced by paclitaxel in a patient with squamous cell carcinoma of the lung: a case report. Anticancer Res 24:1135–7

    PubMed  Google Scholar 

  73. Sawada Y, Sugita K, Kabashima R, Nakamura M, Tokura Y (2009) Docetaxel-induced Stevens-Johnson syndrome with regenerating epidermis composed of atypical keratinocytes. J Eur Acad Dermatol Venereol 23:1333–5

    Article  CAS  PubMed  Google Scholar 

  74. Taj A (2013) Docetaxel-induced hypersensitivity pneumonitis mimicking lymphangitic carcinomatosis in a patient with metastatic adenocarcinoma of the lung. Hematol Oncol Stem Cell Ther 6:117–9

    Article  PubMed  Google Scholar 

  75. Nagata S, Ueda N, Yoshida Y, Matsuda H, Maehara Y (2010) Severe interstitial pneumonitis associated with the administration of taxanes. J Infect Chemother 16:340–4

    Article  PubMed  Google Scholar 

  76. Read WL, Mortimer JE, Picus J (2002) Severe interstitial pneumonitis associated with docetaxel administration. Cancer 94:847–53

    Article  PubMed  Google Scholar 

  77. Von Hoff DD, Ervin T, Arena FP et al (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369:1691–703

    Article  CAS  Google Scholar 

  78. Fujimori K, Yokoyama A, Kurita Y, Uno K, Saijo N (1998) Paclitaxel-induced cell-mediated hypersensitivity pneumonitis. Diagnosis using leukocyte migration test, bronchoalveolar lavage and transbronchial lung biopsy. Oncology 55:340–4

    Article  CAS  PubMed  Google Scholar 

  79. Chen M, Crowson AN, Woofter M, Luca MB, Magro CM (2004) Docetaxel (taxotere) induced subacute cutaneous lupus erythematosus: report of 4 cases. J Rheumatol 31:818–20

    PubMed  Google Scholar 

  80. Marchetti MA, Noland MM, Dillon PM, Greer KE (2013) Taxane associated subacute cutaneous lupus erythematosus. Dermatol Online J 19:19259

    CAS  PubMed  Google Scholar 

  81. Lamond NW, Younis T, Purdy K, Dorreen MS (2013) Drug-induced subacute cutaneous lupus erythematosus associated with nab-paclitaxel therapy. Curr Oncol 20:e484–7

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  82. Robinson JB, Singh D, Bodurka-Bevers DC, Wharton JT, Gershenson DM, Wolf JK (2001) Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies. Gynecol Oncol 82:550–8

    Article  CAS  PubMed  Google Scholar 

  83. Raisch DW, Campbell W, Garg V et al (2011) Description of anaphylactic reactions to paclitaxel and docetaxel reported to the FDA, with a focus on the role of premedication. Expert Opin Drug Saf 10:521–8

    Article  CAS  PubMed  Google Scholar 

  84. Bennett CL, Adegboro OS, Calhoun EA, Raisch D (2010) Beyond the black box: drug- and device-associated hypersensitivity events. Drug Healthc Patient Saf 2:1–5

    Article  PubMed Central  PubMed  Google Scholar 

  85. Szebeni J, Muggia FM, Alving CR (1998) Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. J Natl Cancer Inst 90:300–6

    Article  CAS  PubMed  Google Scholar 

  86. Weiszhar Z, Czucz J, Revesz C, Rosivall L, Szebeni J, Rozsnyay Z (2012) Complement activation by polyethoxylated pharmaceutical surfactants: Cremophor-EL, Tween-80 and Tween-20. Eur J Pharm Sci 45:492–8

    Article  CAS  PubMed  Google Scholar 

  87. Essayan DM, Kagey-Sobotka A, Colarusso PJ, Lichtenstein LM, Ozols RF, King ED (1996) Successful parenteral desensitization to paclitaxel. J Allergy Clin Immunol 97:42–6

    Article  CAS  PubMed  Google Scholar 

  88. Madrigal-Burgaleta R, Berges-Gimeno MP, Angel-Pereira D et al (2013) Hypersensitivity and desensitization to antineoplastic agents: outcomes of 189 procedures with a new short protocol and novel diagnostic tools assessment. Allergy 68:853–61

    Article  CAS  PubMed  Google Scholar 

  89. Gastaminza G, de la Borbolla JM, Goikoetxea MJ et al (2011) A new rapid desensitization protocol for chemotherapy agents. J Investig Allergol Clin Immunol 21:108–12

    CAS  PubMed  Google Scholar 

  90. Ebo DG, Piel GC, Conraads V, Stevens WJ (2001) IgE-mediated anaphylaxis after first intravenous infusion of cyclosporine. Ann Allergy Asthma Immunol 87:243–5

    Article  CAS  PubMed  Google Scholar 

  91. Perez-Perez L, Garcia-Gavin J, Pineiro B, Zulaica A (2011) Biologic-induced urticaria due to polysorbate 80: usefulness of prick test. Br J Dermatol 164:1119–20

    Article  CAS  PubMed  Google Scholar 

  92. Limaye S, Steele RH, Quin J, Cleland B (2002) An allergic reaction to erythropoietin secondary to polysorbate hypersensitivity. J Allergy Clin Immunol 110:530

    Article  PubMed  Google Scholar 

  93. van Zuylen L, Gianni L, Verweij J et al (2000) Inter-relationships of paclitaxel disposition, infusion duration and Cremophor EL kinetics in cancer patients. Anticancer Drugs 11:331–7

    Article  PubMed  Google Scholar 

  94. Vanhaelen M, Duchateau J, Vanhaelen-Fastre R, Jaziri M (2002) Taxanes in Taxus baccata pollen: cardiotoxicity and/or allergenicity? Planta Med 68:36–40

    Article  CAS  PubMed  Google Scholar 

  95. Lakin JD, Blocker TJ, Strong DM, Yocum MW (1978) Anaphylaxis to protamine sulfate mediated by a complement-dependent IgG antibody. J Allergy Clin Immunol 61:102–7

    Article  CAS  PubMed  Google Scholar 

  96. Weiss ME, Adkinson NF Jr (1991) Allergy to protamine. Clin Rev Allergy 9:339–55

    CAS  PubMed  Google Scholar 

  97. Dykewicz MS, Kim HW, Orfan N, Yoo TJ, Lieberman P (1994) Immunologic analysis of anaphylaxis to protamine component in neutral protamine Hagedorn human insulin. J Allergy Clin Immunol 93:117–25

    Article  CAS  PubMed  Google Scholar 

  98. Maguchi S, Fukuda S (2001) Taxus cuspidata (Japanese yew) pollen nasal allergy. Auris Nasus Larynx 28(Suppl):S43–7

    Article  PubMed  Google Scholar 

  99. Italian Association of Aerobiology (2002) An epidemiological survey of Cupressaceae pollenosis in Italy. J Investig Allergol Clin Immunol 12:287–92

    Google Scholar 

  100. Joint Task Force on Practice Parameters; American Academy of Allergy, Asthma and Immunology; American College of Allergy, Asthma and Immunology; Joint Council of Allergy, Asthma and Immunology (2010) Drug allergy: an updated practice parameter. Ann Allergy Asthma Immunol 105:259–73

    Google Scholar 

  101. Brown SG (2004) Clinical features and severity grading of anaphylaxis. J Allergy Clin Immunol 114:371–6

    Article  PubMed  Google Scholar 

  102. Peereboom DM, Donehower RC, Eisenhauer EA et al (1993) Successful re-treatment with taxol after major hypersensitivity reactions. J Clin Oncol 11:885–90

    CAS  PubMed  Google Scholar 

  103. Markman M, Kennedy A, Webster K, Peterson G, Kulp B, Belinson J (2001) Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum. J Clin Oncol 19:1901–5

    CAS  PubMed  Google Scholar 

  104. Laskin MS, Lucchesi KJ, Morgan M (1993) Paclitaxel rechallenge failure after a major hypersensitivity reaction. J Clin Oncol 11:2456–7

    CAS  PubMed  Google Scholar 

  105. Del Priore G, Smith P, Warshal DP, Dubeshter B, Angel C (1995) Paclitaxel-associated hypersensitivity reaction despite high-dose steroids and prolonged infusions. Gynecol Oncol 56:316–8

    Article  PubMed  Google Scholar 

  106. Feldweg AM, Lee CW, Matulonis UA, Castells M (2005) Rapid desensitization for hypersensitivity reactions to paclitaxel and docetaxel: a new standard protocol used in 77 successful treatments. Gynecol Oncol 96:824–9

    Article  CAS  PubMed  Google Scholar 

  107. Lokich J, Anderson N (1998) Paclitaxel hypersensitivity reactions: a role for docetaxel substitution. Ann Oncol 9:573

    Article  CAS  PubMed  Google Scholar 

  108. Moon C, Verschraegen CF, Bevers M, Freedman R, Kudelka AP, Kavanagh JJ (2000) Use of docetaxel (Taxotere) in patients with paclitaxel (Taxol) hypersensitivity. Anticancer Drugs 11:565–8

    Article  CAS  PubMed  Google Scholar 

  109. Dizon DS, Schwartz J, Rojan A et al (2006) Cross-sensitivity between paclitaxel and docetaxel in a women's cancers program. Gynecol Oncol 100:149–51

    Article  CAS  PubMed  Google Scholar 

  110. Sanchez-Munoz A, Jimenez B, Garcia-Tapiador A et al (2011) Cross-sensitivity between taxanes in patients with breast cancer. Clin Transl Oncol 13:904–6

    Article  CAS  PubMed  Google Scholar 

  111. Lee CW, Matulonis UA, Castells MC (2005) Rapid inpatient/outpatient desensitization for chemotherapy hypersensitivity: standard protocol effective in 57 patients for 255 courses. Gynecol Oncol 99:393–9

    Article  PubMed  Google Scholar 

  112. Sancho-Serra Mdel C, Simarro M, Castells M (2011) Rapid IgE desensitization is antigen specific and impairs early and late mast cell responses targeting FcepsilonRI internalization. Eur J Immunol 41:1004–13

    Article  PubMed  CAS  Google Scholar 

  113. Zhao W, Gomez G, Macey M, Kepley CL, Schwartz LB (2012) In vitro desensitization of human skin mast cells. J Clin Immunol 32:150–60

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  114. Oka T, Rios EJ, Tsai M, Kalesnikoff J, Galli SJ (2013) Rapid desensitization induces internalization of antigen-specific IgE on mouse mast cells. J Allergy Clin Immunol 132:922–32 e1-16

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  115. Sampson HA, Munoz-Furlong A, Campbell RL et al (2006) Second symposium on the definition and management of anaphylaxis: summary report—Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol 117:391–7

    Article  PubMed  Google Scholar 

  116. Rueff F, Przybilla B, Bilo MB et al (2009) Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy: importance of baseline serum tryptase—a study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom Hypersensitivity. J Allergy Clin Immunol 124:1047–54

    Article  CAS  PubMed  Google Scholar 

  117. Breslow RG, Caiado J, Castells MC (2009) Acetylsalicylic acid and montelukast block mast cell mediator-related symptoms during rapid desensitization. Ann Allergy Asthma Immunol 102:155–60

    Article  CAS  PubMed  Google Scholar 

  118. Fanning LB, Boyce JA (2013) Lipid mediators and allergic diseases. Ann Allergy Asthma Immunol 111:155–62

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  119. Messaad D, Sablayrolles P, Pujol JL, Demoly P (2003) Successful docetaxel tolerance induction. Allergy 58:1320–1

    Article  CAS  PubMed  Google Scholar 

  120. Picard M, Giavina-Bianchi P, Mezzano V, Castells M (2013) Expanding spectrum of mast cell activation disorders: monoclonal and idiopathic mast cell activation syndromes. Clin Ther 35:548–62

    Article  CAS  PubMed  Google Scholar 

  121. Brockow K, Romano A, Blanca M, Ring J, Pichler W, Demoly P (2002) General considerations for skin test procedures in the diagnosis of drug hypersensitivity. Allergy 57:45–51

    CAS  PubMed  Google Scholar 

Download references

Conflicts of Interest

Matthieu Picard and Mariana C. Castells declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Division of Rheumatology, Immunology and Allergy, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, 1 Jimmy Fund Way, Smith Building, Boston, MA, 02115, USA

    Matthieu Picard & Mariana C. Castells

Authors
  1. Matthieu Picard
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mariana C. Castells
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mariana C. Castells.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Picard, M., Castells, M.C. Re-visiting Hypersensitivity Reactions to Taxanes: A Comprehensive Review. Clinic Rev Allerg Immunol 49, 177–191 (2015). https://doi.org/10.1007/s12016-014-8416-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12016-014-8416-0

Keywords

Search

Navigation